Prostate Cancer Reports


Volume 1 Supplement 3
 March 2013
Home > Prostate Cancer Reports > Volume 1 - Year 2013 > Supplement 3, March 2013

CONTENTS



Clinical & Lab investigations
Localized PCa
Low-risk PCa
Intermediate-risk PCa
High-risk PCa


CLINICAL & LAB INVESTIGATIONS


Functional outcomes

Ilic D, Hindson B, Duchesne G, Millar JL.
A randomised, double-blind, placebo-controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer.
J Med Imaging Radiat Oncol. 2013 Feb;57(1):81-8. doi: 10.1111/j.1754-9485.2012.02461.x. Epub 2012 Oct 18.
Abstract | Full text | Related citations


Nomograms

Garzotto M, Beer TM, Hudson RG, Peters L, Hsieh YC, Barrera E, Klein T, Mori M.
Improved detection of prostate cancer using classification and regression tree analysis.
J Clin Oncol. 2005 Jul 1;23(19):4322-9. Epub 2005 Mar 21.
Abstract | Full text | Related citations


Nam RK, Toi A, Klotz LH, Trachtenberg J, Jewett MA, Appu S, Loblaw DA, Sugar L, Narod SA, Kattan MW.
Assessing individual risk for prostate cancer.
J Clin Oncol. 2007 Aug 20;25(24):3582-8.
Abstract | Full text | Related citations


Overviews

Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL; American Society of Clinical Oncology.
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
J Clin Oncol. 2009 Feb 10;27(5):812-26. doi: 10.1200/JCO.2008.21.2134. Epub 2008 Dec 22. Erratum in: J Clin Oncol. 2009 Jun 20;27(18):3070-1.
Abstract | Full text | Erratum | Related citations


Prostate-specific antigen

Chang SL, Harshman LC, Presti JC Jr.
Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey.
J Clin Oncol. 2010 Sep 1;28(25):3951-7. doi: 10.1200/JCO.2009.27.9406. Epub 2010 Aug 2.
Abstract | Full text | Related citations


Strope SA, Andriole GL.
Improving prostate-specific antigen screening.
J Clin Oncol. 2010 May 20;28(15):2491-2. doi: 10.1200/JCO.2009.26.9779. Epub 2010 Apr 26
Abstract | Full text | Related citations


Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K, Scardino PT, Schröder F, Lilja H.
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.
J Clin Oncol. 2010 May 20;28(15):2493-8. doi: 10.1200/JCO.2009.24.1968. Epub 2010 Apr 26.
Abstract | Full text | Related citations


Vickers AJ, Savage C, O'Brien MF, Lilja H.
Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
J Clin Oncol. 2009 Jan 20;27(3):398-403. doi: 10.1200/JCO.2008.18.1685. Epub 2008 Dec 8.
Abstract | Full text | Related citations


Recurrence

Wachter S, Tomek S, Kurtaran A, Wachter-Gerstner N, Djavan B, Becherer A, Mitterhauser M, Dobrozemsky G, Li S, Pötter R, Dudczak R, Kletter K.
11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.
J Clin Oncol. 2006 Jun 1;24(16):2513-9. Epub 2006 Apr 24.
Abstract | Full text | Related citations


Treatment comparisons

Barry MJ, Gallagher PM, Skinner JS, Fowler FJ Jr.
Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men.
J Clin Oncol. 2012 Feb 10;30(5):513-8. doi: 10.1200/JCO.2011.36.8621. Epub 2012 Jan 3.
Abstract | Full text | Related citations


Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Fung S, Alibhai S, Jewett M, Fleshner N.
Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial.
J Clin Oncol. 2011 Feb 1;29(4):362-8. doi: 10.1200/JCO.2010.31.7305. Epub 2010 Dec 13.
Abstract | Full text | Related citations


Pardo Y, Guedea F, Aguiló F, Fernández P, Macías V, Mariño A, Hervás A, Herruzo I, Ortiz MJ, Ponce de León J, Craven-Bratle J, Suárez JF, Boladeras A, Pont À, Ayala A, Sancho G, Martínez E, Alonso J, Ferrer M.
Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment.
J Clin Oncol. 2010 Nov 1;28(31):4687-96. doi: 10.1200/JCO.2009.25.3245. Epub 2010 Oct 4. Erratum in: J Clin Oncol. 2011 Feb 20;29(6):779.
Abstract | Full text | Erratum | Related citations


Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y, Vickers A, Scardino PT.
Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix.
J Clin Oncol. 2010 Mar 20;28(9):1508-13. doi: 10.1200/JCO.2009.22.2265. Epub 2010 Feb 16.
Abstract | Full text | Related citations

LOCALIZED PROSTATE CANCER


Functional outcomes

Chen RC, Clark JA, Talcott JA.
Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function.
J Clin Oncol. 2009 Aug 20;27(24):3916-22. doi: 10.1200/JCO.2008.18.6486. Epub 2009 Jul 20.
Abstract | Full text | Related citations


Mortality



Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, Klein EA, Wood DP, Scardino PT.
Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
J Clin Oncol. 2009 Sep 10;27(26):4300-5. doi: 10.1200/JCO.2008.18.2501. Epub 2009 Jul 27.
Abstract | Full text | Related citations

LOW-RISK PROSTATE CANCER


Active surveillance

Shappley WV 3rd, Kenfield SA, Kasperzyk JL, Qiu W, Stampfer MJ, Sanda MG, Chan JM.
Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort.
J Clin Oncol. 2009 Oct 20;27(30):4980-5. doi: 10.1200/JCO.2008.21.2613. Epub 2009 Aug 31.
Abstract | Full text | Related citations


Mortality

D'Amico AV, Chen MH.
Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
J Clin Oncol. 2009 Aug 1;27(22):3575-6. doi: 10.1200/JCO.2009.22.6068. Epub 2009 Jun 8.
Abstract | Full text | Related citations


O'Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, Scardino PT, Eastham JA, Vickers AJ, Lilja H.
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
J Clin Oncol. 2009 Aug 1;27(22):3591-7. doi: 10.1200/JCO.2008.19.9794. Epub 2009 Jun 8.
Abstract | Full text | Related citations

INTERMEDIATE-RISK PROSTATE CANCER


Recurrence

Abern MR, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ.
Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database.
Prostate. 2013 Mar;73(4):409-17. doi: 10.1002/pros.22582. Epub 2012 Sep 19.
Abstract | Related citations

HIGH-RISK PROSTATE CANCER


Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, Akaza H.
Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.
J Clin Oncol. 2009 Sep 10;27(26):4306-13. doi: 10.1200/JCO.2008.21.5228. Epub 2009 Aug 10.
Abstract | Full text | Related citations